Posts

Be careful what you wish for: Method of treatment claim for an antibody genus found to satisfy both written description and enablement requirement (Teva v Eli Lilly)

Strict US written description and enablement requirement applied to ADCs and platform inventions (Seagen v Daiichi Sankyo)

Will functional antibody inventions find new life in the US with mean-plus-function claims? (Ex parte Chamberlain, Appeal No. 2022-001944)

Sufficiency of broad functional genus and first medical use claims in Europe (T 0424/21)

Strict US written description requirement applied to CAR-T-cell therapy (Juno v Kite)